Novel cytokine ZCYTO18
OwnerScott R. Presnell, Wayne Kindsvogelinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to ZCYTO18 polynucleotide and polypeptide molecules. The ZCYTO18 is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
Claims28
An isolated polynucleotide that encodes a cytokine polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 23 (Pro), to amino acid number 167 (Ile);
- (b) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 1 (Met), to amino acid number 167 (Ile);
- and
- (c) the amino acid sequence as shown in SEQ ID NO:
- 2 from amino acid number 1 (Met), to amino acid number 179 (Ile);
- and
- wherein the polypeptide produced by the cell induces proliferation of cells expressing a receptor for the polypeptide comprising zcytor11 (SEQ ID NO:
- 19) or induces cytotoxicity in K562 cells.
An expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a cytokine polypeptide as shown in SEQ ID NO:
- 3 from amino acid number 23 (Pro), to amino acid number 167 (Ile);
- and
- a transcription terminator,
- wherein the promoter is operably linked to the DNA segment, and the DNA segment is operably linked to the transcription terminator.
A DNA construct encoding a fusion protein, the DNA construct comprising:
- a first DNA segment encoding a polypeptide comprising a sequence of amino acid residues selected from the group consisting of:
- (a) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 1 (Met), to amino acid number 21 (Ala);
- (b) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 41 (Thr), to amino acid number 53 (Leu);
- (c) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 80 (Met), to amino acid number 91 (Val);
- (d) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 103 (Gln), to amino acid number 116 (Arg);
- (e) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 149 (Ile), to amino acid number 162 (Leu);
- and
- (f) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 23 (Pro), to amino acid number 167 (Ile);
- and
- at least one other DNA segment encoding an additional polypeptide,
- wherein the first and other DNA segments are connected in-frame;
- and
- wherein the first and other DNA segments encode the fusion protein.
An isolated cytokine polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 23 (Pro), to amino acid number 167 (Ile);
- (b) the amino acid sequence as shown in SEQ ID NO:
- 3 from amino acid number 1 (Met), to amino acid number 167 (Ile);
- and
- (c) the amino acid sequence as shown in SEQ ID NO:
- 2 from amino acid number 1 (Met), to amino acid number 179 (Ile);
- and
- wherein the polypeptide produced by the cell induces proliferation of cells expressing a receptor for the polypeptide comprising zcytor11 (SEQ ID NO:
- 19) or induces cytotoxicity in K562 cells.
A method of detecting, in a test sample, the presence of an agonist of ZCYTO18 protein activity, comprising:
- culturing a cell that is responsive to a ZCYTO18-stimulated cellular pathway;
- and
- adding a test sample;
- and
- comparing levels of response in the presence and absence of the test sample, by a biological or biochemical assay;
- and
- determining from the comparison, the presence of the agonist of ZCYTO18 activity in the test sample.
A method for detecting a genetic abnormality in a patient, comprising:
- obtaining a genetic sample from a patient;
- producing a first reaction product by incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:
- 1 or the complement of SEQ ID NO:
- 1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence;
- visualizing the first reaction product;
- and comparing said first reaction product to a control reaction product from a wild type patient, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.
A method for detecting a cancer in a patient, comprising:
- obtaining a tissue or biological sample from a patient;
- labeling a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:
- 1 or the complement of SEQ ID NO:
- 1;
- incubating the tissue or biological sample with under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence;
- visualizing the labeled polynucleotide in the tissue or biological sample;
- and
- comparing the level of labeled polynucleotide hybridization in the tissue or biological sample from the patient to a normal control tissue or biological sample,
- wherein an increase or decrease in the labeled polynucleotide hybridization to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.
A method for detecting inflammation in a patient, comprising:
- obtaining a tissue or biological sample from a patient;
- labeling a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:
- 1 or the complement of SEQ ID NO:
- 1;
- incubating the tissue or biological sample with under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence;
- visualizing the labeled polynucleotide in the tissue or biological sample;
- and
- comparing the level of labeled polynucleotide hybridization in the tissue or biological sample from the patient to a normal control tissue or biological sample,
- wherein an increase in the labeled polynucleotide hybridization to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of inflammation in the patient.
Dependencies are inferred from the claim text.